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Abstract 
Introduction. KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) mutations occur in 
approximately one-third of colorectal (CRC) tumours and have been associated with poor 
prognosis and resistance to some therapeutics. In addition to the well-documented pro-
tumorigenic role of mutant Ras alleles, there is some evidence suggesting that not all KRAS 
mutations are equal and the position and type of amino acid substitutions regulate 
biochemical activity and transforming capacity of KRAS mutations.  
 
Objectives. To investigate the metabolic signatures associated with different KRAS mutations 
in codons 12, 13, 61 and 146 and to determine what metabolic pathways are affected by 
different KRAS mutations.  
 
Methods. We applied an NMR-based metabonomics approach to compare the metabolic 
profiles of the intracellular extracts and the extracellular media from isogenic human SW48 
CRC cell lines with different KRAS mutations in codons 12 (G12D, G12A, G12C, G12S, 
G12R, G12V), 13 (G13D), 61 (Q61H) and 146 (A146T) with their wild-type counterpart. We 
used false discovery rate (FDR)-corrected analysis of variance (ANOVA) to determine 
metabolites that were statistically significantly different in concentration between the 
different mutants. 
 
Results. CRC cells carrying distinct KRAS mutations exhibited differential metabolic 
remodelling, including differences in glycolysis, glutamine utilization and in amino acid, 
nucleotide and hexosamine metabolism.  
 
Conclusions. Metabolic differences among different KRAS mutations might play a role in 
their different responses to anticancer treatments and hence could be exploited as novel 
metabolic vulnerabilities to develop more effective therapies against oncogenic KRAS. 
 
Keywords: KRAS, mutations, colorectal cancer, metabonomics, metabolomics, metabolic 
profiling, NMR 
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Introduction 
KRAS is a gene that has the potential to cause cancer when it is mutated i.e. it is an oncogene. 
Point mutations in the KRAS gene are present in approximately 35–45 % of colorectal 
cancers(Dinu et al, 2014; Tan & Du, 2012), and serve as a negative predictive factor of 
response to anti-EGFR therapy(Lievre et al, 2006). These mutations lead to the loss of 
intrinsic GTPase activity and therefore to increased proliferation and resistance to 
apoptosis(Jia et al, 2017). The majority of KRAS mutations occur in codons 12 and 13, while 
other mutations, such as those in codons 61 and 146 are less common(Guarnaccia et al, 2018; 
Margonis et al, 2015; Stolze et al, 2015). The most common point mutations in codon 12 and 
13 are codon 12 Gly→Asp (G12D), codon 12 Gly→Val (G12V), and codon 13 Gly→Asp 
(G13D) substitutions(Seekhuntod et al, 2016). It is well known that not all KRAS mutations 
are equivalent and the position and type of amino acid substitutions regulate both the 
biochemical activity and transforming capacity of KRAS mutations(Brunelli et al, 2014). For 
example, it has been reported that mutations of KRAS at codon 12 have greater transforming 
ability than at codon 13 and are linked with a more aggressive cancer phenotype, although, 
patients with codon 13 mutations exhibit a markedly worse prognosis(Yokota, 2012). 
Moreover, it has been suggested that different KRAS mutations display different responses to 
treatments. For instance, patients with G13D mutations have been shown to respond better to 
anti-EGFR therapy compared to patients with other KRAS mutations(Kishiki et al, 2014; 
Stolze et al, 2015; Tural et al, 2013).  
Oncogenic KRAS has been shown to promote the decoupling of glycolysis and TCA 
metabolism, with glutamine fuelling the TCA cycle as an alternative source of carbon(Son et 
al, 2013). These findings support the notion that oncogenic KRAS plays a key role in the 
metabolic reprogramming of cancer cells(Vizan et al, 2005; Ying et al, 2012). Moran et al 
found that KRAS mutation was associated with increased dependency on folate metabolism in 
non-small cell lung cancer cells(Moran et al, 2014). A panel of KRAS mutants in isogenic 
SW48 colon cancer cell lines exhibited a unique signalling network signature and proteome 
expression profile(Hammond et al, 2015). In addition, Kerr et al demonstrated that 
homozygous KRAS G12D/G12D cells had a glycolytic switch and increased channelling of 
glucose-derived metabolites into the TCA cycle and glutathione biosynthesis(Kerr et al, 
2016). However, in spite of all this work, the overall metabolic dysregulation driven by 
different KRAS mutations in colorectal cancer is still not clear.  
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Since metabolic reprogramming is a hallmark of cancer and differential metabolic 
reprogramming is important in the development and selection of effective therapies, we 
applied an exploratory, NMR-based metabonomics approach to characterize the metabolic 
pathways affected in isogenic SW48 cells harbouring different KRAS mutations at codons 12, 
13, 61 and 146. Not only will this work help explain why different KRAS mutations give rise 
to different cancer metabolism and phenotypic outcomes but also, the identification of 
metabolic pathways associated with specific KRAS mutations may be of use in the design of 
more effective targeted therapies for colorectal cancer in the future. 
 
Materials and Methods 
Cell culture  
Isogenic SW48 colorectal carcinoma cell lines were sourced from Horizon Discovery Ltd 
(Cambridge, UK). All of these cell lines were generated using a recombinant Adeno-
Associated Virus (rAAV)-based gene editing platform according to published methods(Arena 
et al, 2007; Vartanian et al, 2013). All cell lines were cultured in McCoy’s 5A medium 
(Gibco, Life Technologies, UK), supplemented with 10% foetal bovine serum (FBS) (Gibco, 
UK). Cells were grown in 150 cm2 cell culture flasks (Corning, UK), incubated at 37 °C in a 
humidified atmosphere containing 5% CO2 and passaged routinely until they reached 
approximately 80–90% confluence. All experiments were performed in five biological 
replicates. 
Cell harvesting method 
The medium was removed from the attached cells in a T150 cm2 flask and the cells were 
washed once with 20 mL phosphate buffered saline (PBS, pH 7.0-7.3, CaCl2- and MgCl2-
free, Gibco, Life Technologies, UK) at room temperature to remove residual serum. 3 ml 
0.05% Trypsin-EDTA (Gibco, Life Technologies, UK) was added to the flasks and these 
were incubated at 37 °C for 3 min. Once the cells had detached (checked using a phase 
contrast inverted microscope) 10 ml of complete medium was added to dilute the trypsin. The 
media containing the detached cells was transferred into a 50 ml conical tube (Fisher 
Scientific, UK). Cells collected from different flasks were mixed into one tube and then 300 
µl of cell suspension was removed for accurate cell counting using a Nucleocounter 
(Chemometec, Denmark). The cell suspension was centrifuged at 1,400 rpm for 5 min at 
room temperature. After removing the media, the cell pellet was suspended in Opti-MEM 
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media (Gibco, Life Technologies, UK) and aliquots (1ml) containing 2 x 107 SW48 cells 
were added in 5 T75 cm2 low adherence flasks (Corning, UK) containing 9 ml of Opti-MEM 
medium.  After incubation at 37 °C for 6 hours, the cells from each flask were harvested and 
transferred into a 15 ml Falcon tube (Fisher Scientific, UK). The cell suspension was 
centrifuged at 1,400 rpm for 5 min at 4°C, the Opti-MEM media was removed and the cell 
pellet was washed once with 10 ml ice cold PBS to remove extracellular metabolites. After 
removing PBS by centrifugation (1,400 rpm and 4 °C for 5 min), the cell pellets were 
immediately frozen in liquid nitrogen and stored at −80 °C. The Opti-MEM media removed 
from SW48 cells was also snap frozen in liquid nitrogen and stored at −80 °C.   
Metabolite Extraction of SW48 cell lines 
Cells were extracted in 1000 μl chilled MeOH/H2O (−20 °C, 80/20 (v/v)) for 30 s at 15 Hz 
using 2ml CK28-R reinforced ceramic homogenising tube and a TissueLyser II (QIAGEN, 
UK). The samples were centrifuged at 4 °C and 7,000×g for 5 min and the supernatant was 
collected into a new Eppendorf tube. The pellet was re-extracted once with 1000 μL cold 
methanol/water (−20 °C, 80/20 (v/v)) to produce 2 ml of extract. The supernatants were 
combined, dried under a gentle flow of N2 gas (Labconco RapidVap evaporator) and stored at 
-80° until NMR analysis. 
Sample preparation for NMR Analysis 
Cell extracts were resuspended by vortexing in 180 μl phosphate buffer (81/19 (v/v) mixture 
of 0.1 M K2HPO4 and NaH2PO4 in 100% 2H2O with 0.1 mM 3-(trimethylsilyl)propionic-
2,2,3,3-d4 acid sodium salt (TSP), pH 7.4). The buffered samples were then centrifuged at 
10,000 rpm for 1 min at 4°C to remove any suspended particles. After centrifugation, the 
supernatant was transferred into 3 mm diameter NMR tubes (SampleJet Tube 3.0 x 103.5mm, 
Bruker Spectrospin; Z112272) using an electronic syringe (SGE-Analytical Science, UK). In 
addition, four SW48 KRAS G13D/+ extracts were pooled for analysis in 5 mm o.d. NMR tubes 
(NORELL, 508-UP-7), in order to provide greater sensitivity for two-dimensional NMR 
experiments for metabolite identification. 
Cell culture medium sample preparation for NMR analysis 
500 μl of Opti-MEM cell medium collected from SW48 cell lines were mixed with 250 ul of 
phosphate buffer (81:19 (v/v) mixture of 0.6 M K2HPO4 and NaH2PO4 in 100% 2H2O, pH 
7.4) containing TSP (0.5mM, Sigma-Aldrich) and sodium azide (9 mM, Sigma-Aldrich). 600 
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μl samples were then transferred into 5mm diameter NMR tubes (Norell, S-1.7-500-1) and 1H 
NMR spectra of cell culture media acquired. 
1H NMR Spectroscopy 
1H NMR spectra of the metabolites were acquired on a 600 MHz Bruker Avance 
spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany) operating at a temperature of 
300.0 K. Standard 1D 1H NMR spectra were acquired with a 1D NOESY pulse sequence 
(RD-90°-t1-90°-tm-90°-acquire, pulse sequence noesygppr1d) with water suppression 
applied during the relaxation delay (RD) of 4 s and mixing time (tm) of 10 ms. 128 transients 
for SW48 culture medium and 256 transients for SW48 cell extracts were collected into 
65,536 data points with a spectral width of 20 ppm. 
Two-dimensional NMR analysis of cell extracts 
Two-dimensional NMR experiments were performed on representative samples to ensure the 
unambiguous assignment of the identities of the metabolites. The detailed parameters for the 
acquisition of the 2D NMR spectra of SW48 KRAS G13D/+and media of SW48 KRAS +/+are 
provided in Supplementary Tables 1 and 2. 
NMR Data treatment  
Prior to Fourier transformation, each free induction decay (FID) was multiplied by an 
exponential function equivalent to a 0.3 Hz line broadening, in order to improve the signal-to-
noise ratio. The resulting spectra were phase corrected, baseline corrected and referenced 
relative to the chemical shift of the methyl protons of TSP (0.0 ppm) using TOPSPIN 3.2 
(Bruker Biospin, UK). The NMR spectra were imported into Matlab (R2010 b, Mathworks) 
and analysed using in-house Matlab routines written by the team of Dr K. Veselkov. The 
regions of the spectra upfield of 0.8 ppm, downfield of 10 ppm and the water region (δ 4.7 – 
5.2) were excluded to eliminate the effects of variable water saturation and background noise. 
All NMR spectra were normalised according to the “Probabilistic Quotient 
Normalization(Dieterle et al, 2006)” method in order to compensate for variations in the 
overall concentrations of the samples. In order to correct chemical shift variations between 
the different samples, due to minor changes in pH, ionic strength and solute composition, 
NMR spectra were aligned using recursive segment-wise peak alignment (RSPA) method. 
After alignment, all NMR data were log-transformed to convert multiplicative noise into 
additive noise(Veselkov et al, 2011). 
Pattern recognition and multivariate data analysis 
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Pattern recognition analyses were performed as described previously(Varshavi et al, 2018). 
Initially, NMR spectral data were subjected to principal component analysis (PCA) to 
visualize the general structure of each data set and to identify sub-groups and any potential 
outliers within the data. Subsequently, a supervised multivariate analysis known as maximum 
margin criterion (MMC) was applied to simultaneously maximize the inter-group differences 
i.e. cell genotypes, whilst minimising within group differences i.e. biological 
replicates.(Veselkov et al, 2014b) The validity of the MMC models was checked by 
performing a “leave-one -out” cross-validation using the quadratic as a classifier. One-way 
analysis of variance (ANOVA) with a false discovery rate (FDR) of 0.1 i.e. 10% to account 
for multiple hypothesis testing(Benjamini, 2010) was employed to determine metabolites that 
individually (irrespective of other metabolites) have a different abundance between groups. 
The FDR approach was used in order to avoid the well-known problems that can arise due to 
multiple hypothesis testing in high dimensional datasets(Benjamini, 2010; Han et al, 2009). 
Metabolite Identification 
Statistically significantly discriminating metabolites were identified by (i) comparison with 
reference spectra from the Human Metabolome Database (HMDB, 
http://www.hmdb.ca/)(Wishart et al, 2007) and the Biological Magnetic Resonance Data 
Bank (BMRB, http://www.bmrb.wisc.edu/metabolomics/); (ii) analysis of previously 
published data; and (iii) the interpretation of a series of two-dimensional (2D) spectra such as 
2D 1H COSY, J-resolved, HSQC and HMBC, using published methods(Dona et al, 2016; 
Everett, 2015). 
 
Results  
Intracellular metabolic profiling of isogenic, human colorectal cancer cells harbouring 
different KRAS mutations in codon 12 and 13 
An unsupervised PCA scores plot of all biological replicates of all SW48 cell lines expressing 
either wild-type or mutant KRAS in either codon 12 or 13 (Figure 1) showed good clustering 
and separation of each mutant from KRAS WT, with the most variability observed between 
G13D and the codon 12 KRAS mutants and the wild-type. These data indicate that each 
activating KRAS mutation generates a unique metabolic signature that is distinct from KRAS 
WT. Representative 1H NMR spectra of three of these isogenic cell lines are shown in 
Supplementary Figure 1. 
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The supervised dimension reduction technique, maximum margin criterion (MMC) 
(Veselkov et al, 2014b) showed somewhat improved class separation (Supplementary Figure 
2). Correct classification rates of 100% were observed for all models. Leave-one-out cross-
validation with the quadratic as a classifier was applied (Supplementary Figure 3). 
One-way ANOVA with a false discovery rate (FDR) of 10%, was used to determine the 
statistically significantly different metabolites between the KRAS mutant cells and their 
KRAS wild type isogenic cell lines (Figure 2 and Supplementary Figures 4 to 9). Table 1 lists 
the statistically significant discriminating metabolites and their associated HMDB 
identification numbers. G12V displayed the most marked metabolic remodelling. All 
metabolites are identified at MSI Level 2(Sumner et al, 2007) and confidently identified by 
MICE methodology.(Everett, 2015) Comparison of relative fold-changes in the significantly 
altered metabolites in each KRAS mutant with their WT counterpart showed that KRAS 
mutations mostly reduced the amount of metabolites relative to WT (Table 2 and 
Supplementary Tables 3 to 8). 
To further understand the biological significance of the metabolite changes in the KRAS 
mutant clones, we used enrichment analysis (EA) tools in MetaboAnalyst to link metabolites 
to metabolic pathways (Figure 3 and Supplementary Figures 10 to 12). In all seven KRAS 
mutant clones, protein biosynthesis, urea cycle, RNA transcription and ammonia recycling 
were over-represented. The levels of amino acids involved in protein synthesis were mostly 
lower in the mutant KRAS clones compared to WT, with the exception of the greater amount 
of aspartate in the G12C, G12D and G12R clones (Supplementary Table 9). All G12 KRAS 
mutants showed a lower level of glutamine. In parallel, both G13 and G12 mutations (except 
for G12A, G12D and G12R, where there was no significant change) had a lower intracellular 
concentration of glutamate, indicating that most KRAS mutations used glutaminolysis to 
provide the energy for growing and proliferation. G12D and G12V mutants also had lower 
intracellular concentrations of NAD+, a vital coenzyme regulating several cellular metabolic 
pathways. Moreover, with the exception of KRAS G12C, all cell lines with mutations in 
codon 12 showed lower levels of UDP-N-acetylglucosamine and UDP-N-
acetylgalactosamine, while KRAS G13D exhibited an increased level of UDP-N-
acetylglucosamine and UDP-N-acetylgalactosamine compared to KRAS WT. All KRAS 
mutants with the exception of KRAS G12S showed lower levels of adenosine 
monophosphate (AMP) and higher levels of inosine and uridine compared to wild type. 
Furthermore, lower levels of UMP were observed in all KRAS mutants except for G12S, 
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G12A and G12R. Analysis of intracellular metabolites in G12 KRAS mutations revealed 
decreased level of GPC in cell lines harbouring G12C, G12D, G12V and G12R mutations. 
Phosphocholine levels were reduced in cell lines with G12R mutation, while the levels of 
choline were increased in G12C and G12R and decreased in G12V. G13D mutants exhibited 
significantly higher levels of GPC compared to WT. Choline levels were not found to be 
significantly different between G13D mutants and WT, while PCho levels were found to be 
lower in mutated cells. While some metabolites showed similar patterns of changes across the 
majority of KRAS mutants, others were unique for each KRAS mutation. For instance, the 
levels of taurine were reduced in cell lines with G13D and G12V mutations, whilst increased 
in cell lines harbouring G12D and G12R mutations. KRAS G13D and G12C also had higher 
intracellular concentrations of myo-inositol, while G12S exhibited reduced levels of myo-
inositol compared to WT. 
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Figure 1. a) PCA scores plot of the 600MHz 1H NMR spectra from extracts of SW48 cells with KRAS mutations in codons 12 and 13 and their wild type 
counterpart, KRAS+/+ ; b) superimposed NMR spectra of SW48 cells, with the same colour coding as in the PCA plot, part a); c) ‘the corresponding heat map 
display of the 600 MHz 1H NMR spectra of SW48 cell lines from 0.8 to 10.0 ppm. Red and blue elements in the spectra indicate NMR signals that are more 
intense, or less intense, respectively, than the median signal intensity for all the samples. 
 Human Colorectal Cancer Cell Mutants REV1 Page 11 of 30 
 
Figure 2. At bottom a ‘heat map display of the 600 MHz 1H NMR spectra of KRAS G13D/+ (top 5 strips) vs the corresponding spectra of parental cell line 
(KRAS+/+) (bottom 4 strips). Red and blue elements in the spectra indicate NMR signals that are more intense, or less intense, respectively, than the median 
signal intensity for all the samples. At top, the corresponding ANOVA plot, showing positive peaks for those metabolite signals that are more intense in 
KRAS G13D/+, and negative peaks for those metabolite signals that are less intense. The signals are colour coded by the p value adjusted for an FDR of 0.1. The 
FDR-adjusted p value for statistically significant difference, pFDR, is 0.018 in this case. 
  
KRAS+/+ 
KRASG13D/+ 
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Table 1. Summary of the most significant metabolites differentiating between SW48 cells with KRAS mutations in codons 12 and 13 and their wild type 
counterpart 
Metabolite 
1H NMR parameters: 
Chemical shift in 
ppm (multiplicity, d 
doublet, m multiplet, 
s singlet, t triplet) 
G13D/+  
vs +/+ 
 
  
 
G12S/+ 
vs +/+ 
G12A/+ 
vs +/+ 
G12C/+ 
vs +/+ 
G12D/+ 
vs +/+ 
G12V/+ 
vs +/+ 
G12R/+ 
vs +/+ 
isoleucine  
HMDB000172 
0.943 (t), 1.01 (d), 
3.675 (d) $ - 
$ 
 $ ↓ ↓ - 
leucine 
HMDB00687 
0.961 (d), 0.972 (d), 
1.691 (m), 1.720 (m), 
1.748 (m), 3.737 (dd)  
$ - $  $ ↓ ↓ - 
valine 
HMDB0000883 
0.996 (d), 1.046 (d), 
3.615 (d) $ - 
$ 
 $ ↓ ↓ - 
lactate 
HMDB00190 1.331 (d), 4.113 (q) - - - - ↓ ↓ - 
threonine  
HMDB0000167 1.335 (d), 3.591 (d)  -  
 
- $ ↓ ↓ - 
alanine 
HMDB0000161 1.485 (d), 3.787 (q)  - 
- 
 - 
 
$ - ↓ - 
UDP-N-acetyl-
glucosamine 
HMDB00290 
2.084 (s), 4.295 (m), 
4.367 (m), 5.523 (dd), 
5.975 (d), 5.991 (d), 
7.958 (d) 
# 
 
$ 
 
$ 
 - ↓ ↓ 
$ 
 
UDP-N-acetyl-
galactosamine 
HMDB0000304 
2.088 (s), 3.770 (m), 
4.255 (m), 5.556 (dd), 
5.975 (d), 5.990 (d) 
 
# 
 
 
$ 
 
 
$ 
 
- ↓ ↓ $  
glutamate 
HMDB0000148 
2.059 (m), 2.140 (m), 
2.355 (m), 3.761 (dd) $ $ - $ - ↓ - 
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glutamine 
HMDB0000641 
2.145 (m), 2.460 (m), 
3.783 (t) - $ $ $ ↓ ↓ $ 
glutathione 
HMDB0000125 
2.171 (m), 2.560 (m),  
2.935 (dd), 2.980 (dd),  
3.782 (m), 4.572 (dd) 
- - 
- 
 
 
$ - ↓ - 
succinate 
HMDB0000254 2.406 (s) - - - $ ↓ ↓ - 
aspartate 
HMDB0000191 
2.684 (dd), 2.816 (dd), 
3.902 (dd) $ $ $ # ↑ - # 
creatine 
HMDB0000064 3.041 (s), 3.931 (s) - - - - - ↓ - 
creatine 
phosphate 
HMDB0001511 
3.045 (s), 3.95 (s)  $ - -  - ↑ ↑ $ 
choline 
HMDB0000097 3.205 (s) - - - # - ↓ 
# 
 
phosphoryl-
choline 
HMDB0001565 
 
3.224 (s), 3.597 (s), 
4.171 (m) 
$ $ - - - - $  
glycerophospho-
choline 
HMDB00086 
3.234 (s), 4.33 (m) #  - - 
$ 
 ↓ ↓ 
$ 
 
taurine 
HMDB0000251 
3.269 (t), 3.425 (t) 
  
 
$ - - - # ↓ # 
myo-inositol 
HMDB0000211 
3.284 (t), 3.540 (dd), 
3.626 (dd), 4.067 (t) 
# 
 
$ 
 - # - - - 
inosine 
HMDB0000195 
 
3.845 (dd), 3.915 (dd), 
4.282 (m), 4.442 (dd), 
6.105 (d), 8.241 (s), 
8.348 (s) 
# 
 - 
# 
 
# 
 
# 
 
# 
 
# 
 
glucose  
HMDB0000122 4.652 (d), 5.239 (d) 
# 
 
# 
 - - - - 
- 
 
 Human Colorectal Cancer Cell Mutants REV1 Page 14 of 30 
uridine 
HMDB0000296 
5.907 (d), 5.922 (d), 
7.877 (d) # - # # # ↑ 
# 
 
GTP  
HMDB0001273 5.945 (d), 8.14 (s) $ $ - $ $ 
$ 
 
$ 
 
UMP 
HMDB0000288 5.97 (d), 8.11 (d) 
$ 
 - - 
$ 
 
$ 
 
$ 
 - 
NAD  
HMDB0000902 
6.044 (d), 6.09 (d), 
8.18 (s), 8.20 , 8.43 (s), 
8.84 (m), 9.15, 9.34  
- 
 - 
- 
 - 
$ 
 
$ 
 - 
fumarate 
HMDB00134 6.521 (s) 
$ 
 - - # - - - 
tyrosine 
HMDB00158 6.91 (m), 7.20 (m) 
$ 
 - 
$ 
 
$ 
 
$ 
 
$ 
 - 
phenylalanine 
HMDB00159 
7.34 (d), 7.381 (m), 
7.43 (m) 
$ 
 - 
$ 
 
$ 
 
$ 
 
$ 
 - 
AMP 
HMDB00045 8.273 (s), 8.614 (s) 
$ 
 - $ 
$ 
 
$ 
 ↓ 
$ 
 
ATP  
HMDB00538 8.275 (s), 8.538 (s) 
$ 
 - 
$ 
 
$ 
 
$ 
 
$ 
 - 
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Table 2. Intracellular metabolites discriminating between KRASG13D/+ and KRAS+/+ 
 
Metabolite1 ppm p-values q-values Log2 FC2 
leucine 0.965 9.83E-03 7.24E-02 -0.352 
isoleucine 1.009 3.20E-03 3.62E-02 -0.405 
valine 1.041 3.68E-03 3.93E-02 -0.403 
glutamate 2.340 8.67E-03 6.67E-02 -0.382 
glutamine 2.440 0.010368 0.075063 -0.167 
aspartate 2.704 1.25E-03 2.12E-02 -0.412 
creatine phosphate 3.045 1.44E-02 9.28E-02 -1.060 
phosphocholine 3.224 3.76E-04 1.09E-02 -0.733 
glycerophosphocholine 3.234 1.07E-03 1.94E-02 0.590 
taurine 3.428 1.16E-03 2.04E-02 -0.776 
myo-inositol 4.067 5.05E-04 1.28E-02 0.681 
AMP 4.518 8.57E-04 1.74E-02 -0.705 
glucose 5.235 1.26E-02 8.52E-02 0.646 
UDP-N-acetylglucosamine 5.512 2.56E-05 3.28E-03 0.659 
UDP-N-
acetylgalactosamine 
5.546 9.92E-06 2.93E-03 0.375 
uridine 5.900 6.47E-03 5.54E-02 0.284 
fumarate 6.521 9.21E-04 1.80E-02 -0.281 
tyrosine 6.899 5.57E-03 5.06E-02 -0.163 
phenylalanine 7.329 5.17E-03 4.84E-02 -0.177 
UMP 8.105 1.61E-03 2.47E-02 -0.483 
GTP 8.140 5.87E-04 1.40E-02 -0.238 
inosine 8.349 2.25E-05 3.24E-03 1.739 
ATP 8.537 1.87E-03 2.68E-02 -0.363 
AMP 8.605 1.53E-03 2.39E-02 -1.435 
1. For HMDB ID numbers, see Table 1 above. 
2. FC: fold change 
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a) 
  
b) 
  
Figure 3. Metabolic pathway analyses for metabolites discriminating between a) KRAS G13D/+and 
KRAS+/+ b) KRAS G12D/+and KRAS+/+. The horizontal bars summarize the main metabolite sets 
identified in this analysis; the bars are coloured based on their p-values and the length is based on the 
fold enrichment 
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Extracellular metabolic profiling of isogenic KRAS wild type and CRC cells with 
mutation in codon 12 and 13  
To better understand metabolite excretion or utilization by cells, we also compared the 
extracellular metabolite profiles of the SW48 colorectal cell lines with KRAS mutation in 
either codon 12 or 13 with their corresponding KRAS wild type cells. Supplementary Figure 
13 shows representative (1D) 1H NMR spectra of culture media (Opti-MEM Medium) from 
three of these SW48 isogenic cell line (KRAS G13D/+, KRAS G12D/+ and KRAS+/+). 
PCA Analysis, showed that all mutant colorectal cancer cell lines were clearly separated from 
the wild-type KRAS controls (Supplementary Figure 14). Whilst several KRAS mutants 
overlapped with each other, samples of KRAS G12D and KRAS G12S deviated from the rest 
of KRAS mutants, and KRAS G12D clustered closer to the KRAS WT. 
Maximum margin criterion (MMC, Supplementary Figure 15) analysis was also 
performed(Veselkov et al, 2014a) and validated (Supplementary Figure 16) and ANOVA 
with an FDR of 0.1 identified metabolites responsible for the group separations 
(Supplementary Figures 17 to 23). 
Table 3 lists the statistically significant extracellular metabolites discriminating between 
SW48 cell lines harbouring KRAS mutations in codon 12 and 13 and their matched wild type 
cells. 
Some metabolites showed similar patterns of changes in the majority of the KRAS mutant 
cells. For instance, all KRAS mutants, with the exception of G13D, G12D and G12S, showed 
an elevated uptake of glucose and release of lactate compared to their matched KRAS wild 
type cells. In addition, an increased uptake of methionine is observed in all KRAS mutant cell 
lines apart from G12D. Moreover, L-alanyl-L-glutamine was decreased across all KRAS 
mutant cell lines except G12C and G12S. However, nutrient utilization generally was varied 
among colorectal cancer cell lines with different KRAS mutations (see Supplementary 
Information page 34 and Supplementary Tables 10 to 16). 
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Table 3. Summary of the most significant extracellular metabolites differentiating between 
media of SW48 cells with KRAS mutations in codons 12 and 13 and media of their wild type 
counterpart 
Metabolite 
(HMDB 
No) 
1H NMR 
chemical 
shift in 
ppm and 
multi-
plicity 
G13D/+  
vs +/+ 
 
  
 
G12S/+ 
vs +/+ 
G12A/+ 
vs +/+ 
G12C/+ 
vs +/+ 
G12D/+ 
vs +/+ 
G12V/+ 
vs +/+ 
G12R/+ 
vs +/+ 
3-methyl-
2-oxo-
valeric acid 
(00491) 
0.897 (t), 
1.102 (d) 
↓ - - ↑ - ↓ ↑ 
keto-
leucine 
(00695) 
0.94(d), 
2.617(d) 
↓ - ↓ - - ↓ - 
isoleucine  
(00172) 
0.943 (t), 
1.01 (d), 
3.675 (d) 
- - - ↓ - - ↓ 
leucine 
(00687) 
0.961 (d), 
0.972 (d), 
1.691 (m), 
1.720 (m), 
1.748 (m), 
3.737 (dd)  
 
- - - ↓ - - ↓ 
valine 
(00883) 
0.996 (d), 
1.046 (d), 
3.615 (d) 
- - - ↓ - - ↓ 
2-oxo-
isovaleric 
acid 
(00019) 
1.126 (d) ↓ - - - - ↓ ↑ 
lactate 
(00190) 
1.331 (d), 
4.113 (q)  
↓ ↓ ↑ ↑ - ↑ ↑ 
threonine  
(00167) 
 
1.335 (d), 
3.591 (d)  
↓ - - - - - - 
alanine 
(00161) 
1.48 (d), 
3.787 (q)  
- ↓ - - ↑ ↑ - 
L-alanyl-L-
glutamine 
(0028685) 
1.546 (d), 
1.98 (m), 
2.35 (t), 
4.182 
↓ ↑ ↓ - ↓ ↓ ↓ 
acetate 
(00042) 
1.919 (s) ↑ ↑ ↑ ↓ - - ↓ 
glutamate 
(00148) 
2.059 (m), 
2.140 (m), 
↑ - - - - ↑ ↑ 
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2.355 (m), 
3.761 (dd) 
glutamine 
(00641) 
2.145 (m), 
2.46 (m), 
3.783 (t) 
- ↓ - - ↑ - - 
methionine 
(0000696) 
 
2.1(s), 
2.65(t) 
↓ ↓ ↓ ↓ - ↓ ↓ 
 
pyruvate 
(0000243) 
 
 
2.379(s) 
 
- - - - ↑ ↑ - 
aspartate 
(00191) 
 
2.684 (dd), 
2.816 (dd), 
3.902 (dd) 
- - - - - - ↓ 
glucose 
(00122) 
4.65 (d),5.2 
(d) 
- - ↓ ↓ - ↓ ↓ 
histidine 
(00177) 
7.115 (d), 
7.922 (d) 
- - - - - - ↓ 
tyrosine 
(0000158) 
6.91 
(m),7.20 
(m) 
- - - - - - ↓ 
phenyl-
alanine 
(0000159) 
7.34 (d), 
7.381 (m), 
7.43 (m) 
↓ - - ↓ - ↓ ↓ 
tryptophan 
(0000929) 
7.55 (d), 
7.75 (d), 
7.29 (s) 
↓ - ↓ ↓ - - ↓ 
formate 
(0000142) 
8.461(s) - - - - - ↓ ↓ 
 
 
Intracellular metabolic profiling of isogenic KRAS wild type and CRC cells with KRAS 
mutations in codon 61 and 146 
Representative annotated NMR spectra for each mutant and WT samples are shown in 
Supplementary Figure 24. PCA revealed clear separation of each mutant from KRAS WT 
(Supplementary Figure 25). Maximum margin criterion analysis was conducted 
(Supplementary Figure 26)(Veselkov et al, 2014a) and leave-one-out cross-validation with 
the quadratic as a classifier (Supplementary Figure 27) gave correct classification rates of 
100% for all models. Supplementary Figures 28, 29 and 30 show the representative ANOVA 
built between (KRAS A146T/+ vs KRAS +/+), (KRAS Q61H/+ vs KRAS +/+) and (KRAS A146T/+ vs 
KRAS Q61H/+ ) respectively. Supplementary Table 17 lists the most significant metabolites 
responsible for discriminating between all three genotypes. KRAS mutations at codon 61 and 
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146 mostly downregulated metabolites relative to the WT, as observed in cells harbouring 
KRAS mutations in codon 12 and 13. 
Both A146T and Q61H KRAS mutations induced alteration of the same metabolic pathways 
with protein biosynthesis being the most enriched pathways in both mutations 
(Supplementary Figure 31 and Supplementary Tables 18 and 19). Interestingly, the least 
metabolic changes were observed between KRAS A146T/+ and KRAS Q61H/+.   
 
Discussion 
Mutations in the Kirsten Ras (KRAS) oncogene occur in 30–40% of colorectal cancers 
(CRCs) and have been associated with poor prognosis and resistance to anti-epidermal 
growth factor receptor (EGFR)-targeted cancer therapy (Andreyev et al, 2001; Arrington et 
al, 2012; Misale et al, 2014; Misale et al, 2012; Phipps et al, 2013; Tougeron et al, 2013) such 
as the monoclonal antibody panitumumab. Recent evidence indicates that not all mutations in 
KRAS have the same biological impact and patients with different KRAS mutations at 
codons 12 and 13 display different responses to treatments(Garassino et al, 2011; Miller & 
Miller, 2011; Stolze et al, 2015; Tural et al, 2013).  
The oncogene KRAS plays a critical role in metabolic reprogramming and metabolic 
interventions are now attracting attention as potential therapeutic modalities(Kawada et al, 
2017; Kimmelman, 2015).  Metabonomics can thus be regarded as a promising tool to gain 
more insight into metabolic deregulation associated with different KRAS mutations, which in 
turn can be used to discover new therapeutic approaches and better direct existing treatments 
of CRC. 
We note that the impact of KRAS on cell growth is only evident when cells are challenged by 
changing their environment, such that the impact of a dominant oncogene becomes more 
apparent. The effects of mutant KRAS in adherent cells, such as SW48, growing on tissue 
culture plastic is not evident (i.e. the cells are not dependent on mutant KRAS for 
proliferation or survival under these conditions). However, the impact of mutant KRAS is 
apparent in adherent cells when they are cultured either on soft agar, or in low adherence 
plates in the absence of foetal calf serum, and hence we selected these conditions. In addition, 
we selected a short cell incubation time of 6 hours, as we wanted to understand the initial 
impact that mutant KRAS has on metabolism in cells under conditions where mutant KRAS 
has the most substantial impact. 
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Following a thorough multivariate and FDR-controlled univariate analysis of the 1H NMR 
spectra, we observed a clear distinction in both the extracellular (media) and intracellular 
metabolic profiles of the KRAS mutant cells versus the KRAS wildtype cells.  
The analysis of the extracellular media revealed increased glucose consumption and lactate 
release in KRAS G12A, KRAS G12C, KRAS G12V and KRAS G12R compared to KRAS 
wild type cell lines. These metabolic changes could indicate enhanced glycolytic flux in these 
KRAS mutants.  This is consistent with the Warburg effect(Vander Heiden et al, 2009; 
Warburg, 1956) and in accordance with previous studies reporting enhanced glucose uptake 
in cells with mutant KRAS through increased expression of the glucose transporter GLUT1, 
which subsequently results in increased glycolysis and lactate production(Bryant et al, 2014; 
Kawada et al, 2017; Yun et al, 2009). Interestingly, lower levels of lactate were observed in 
the extracellular media of KRAS G13D and KRAS G12S and intracellular extracts of KRAS 
G12D compared to their wild type counterpart. This implies that glycolytic flux and lactate 
production are affected by specific mutations in KRAS. It is already known that a glycolytic 
switch occurs in KRAS G12D/G12D cells (Kerr et al, 2016) 
Decreased levels i.e. elevated consumption of extracellular methionine was observed in all 
KRAS mutant cell lines, with the exception of G12D, relative to their KRAS wild type 
counterpart. Methionine is a sulfur-containing, essential amino acid that plays a critical role 
in many biological functions within carcinogenic processes. Methionine is involved in 
cellular processes and is the immediate precursor of S-adenosyl methionine (SAMe), which is 
a substrate for polyamine synthesis and a key metabolite in one-carbon metabolism, serving 
as a major methyl donor in a multitude of cellular methylation reactions, including the 
methylation of cytosine bases on DNA (Cavuoto & Fenech, 2012). Aberrations in DNA 
methylation have been shown to be associated with colorectal carcinogenesis(Kim, 2004). 
Many cancer-cell types exhibit an increased requirement for methionine (Vazquez et al, 
2016). Thus, methionine restriction can potentially be exploited to treat cancers that exhibit 
methionine dependency, as diet is known to influence methionine metabolism in addition to 
methionine pathway mutations (Sanderson et al, 2019a; Sanderson et al, 2019b) 
Decreased levels of the media component L-alanyl-L-glutamine (stable and non-toxic 
glutamine source) were found for colorectal cancer cells harbouring G13D, G12A, G12D, 
G12V and G12R mutations compared to their background-matched KRAS wild type cancer 
cells. No trace of L-alanyl-L-glutamine was observed in the intracellular matrix indicating 
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either that L-alanyl-L-glutamine is hydrolysed by extracellular peptidase activity, or if it is 
imported, it remains at low levels undetectable by NMR spectroscopy. 
Lowered levels of media L-alanyl-L-glutamine with no changes in extracellular glutamine in 
KRAS G13D, G12A, G12V and G12R relative to WT KRAS could indicate an elevated 
glutamine uptake. KRAS G12D also showed significant decrease of L-alanyl-L-glutamine 
(fold change of ca. 0.16) but with a minor increase of extracellular glutamine (fold change of 
ca. 1.13) compared to WT KRAS, also indicating enhanced glutamine uptake. KRAS G12C, 
however, displayed no changes in either L-alanyl-L-glutamine or extracellular glutamine 
compared to WT KRAS, which is interesting as this specific KRAS mutation is now targeted 
with drugs in the clinic.(Canon et al, 2019; Hallin et al, 2019; Seton-Rogers, 2019) Finally, 
KRAS G12S showed less glutamine uptake as suggested by higher levels of L-alanyl-L-
glutamine and lower levels of extracellular glutamine indicating less hydrolysis of the 
dipeptide. Notably, all KRAS mutants, with the exception of KRAS G13D, showed lower 
intracellular levels of glutamine indicating increased glutamine consumption.  
Glutamine is one of the most important nutrients that is metabolised by many human cancer 
cell lines. Despite being a non-essential amino acid (NEAA) that can be synthesized de novo, 
many cancer cells in vitro largely depend on exogenous glutamine for their growth, 
proliferation, and survival(Choi & Park, 2018). Once imported into the cells, glutamine 
provides a carbon source to fuel the tricarboxylic acid (TCA) cycle and a nitrogen source for 
the biosynthesis of nucleotides, NEAA and hexosamines(Kawada et al, 2017). Cancer cells, 
particularly those harbouring oncogenic KRAS, have been shown to be heavily dependent on 
glutamine for survival and proliferation(Choi & Park, 2018). Overall, our observations 
suggest that KRAS mutations generally induce glutamine dependency with different 
mutations showing different extents of dependency on extracellular glutamine.   
Analysis of the intracellular metabolic profile of the isogenic cell lines showed significant 
variation in a number of metabolic pathways between WT KRAS-expressing cells and all the 
other mutants. The main alterations associated with mutant KRAS involved changes in amino 
acid and nucleotide metabolism as well as in the hexosamine biosynthesis pathway. 
Intracellular glutamate levels were also decreased in most KRAS mutant colorectal cancer 
cells (KRAS G13D, KRAS G12S, KRAS G12C and KRAS G12V). Intracellular glutamate is 
primarily a product of glutamine, which is produced by the action of glutaminase (Kawada et 
al, 2017). Low intracellular levels of glutamine and glutamate in KRAS mutant cells 
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compared to their isogenic wildtype cell lines could indicate sustained biosynthetic reactions 
and a prominent role of glutaminolysis.  
Interestingly, we also observed enhanced intracellular metabolism of other amino acids such 
as tyrosine, phenylalanine, and the branched chain amino acids (BCAAs) leucine, isoleucine, 
and valine in all KRAS mutants, with the exception of G12S and G12R, compared to their 
wild type counterpart. BCAAs are essential for cancer growth and are used by cancer cells in 
various biosynthetic pathways and as a source of energy(Ananieva & Wilkinson, 2018). 
Previous studies have highlighted that leucine, isoleucine, valine, tyrosine and phenylalanine 
contribute to the TCA cycle via conversion into succinate and fumarate(Owen et al, 2002; 
Tripathi et al, 2012). Mayers et al. reported that elevated patient plasma BCAA levels were 
associated with an increased risk of future pancreatic cancer.(Mayers et al, 2014) They also 
reported that changes in BCAA levels in KRAS-driven tumours in mice were tissue 
specific.(Mayers et al, 2016) 
All KRAS mutants except G12C showed decreased levels of UDP-GlcNAc while KRAS 
G13D exhibited an increased amount of UDP-GlcNAc relative to the wild type. UDP-
GalNAc was also decreased in all KRAS mutants except G12C, A146T and Q61H compared 
to the WT counterpart while G13D showed increased levels. Cancer cells generally exhibit 
upregulation of hexosamine biosynthetic pathway (HBP) HBP, which is in turn linked to 
aberrant O-GlcNAcylation and an enhanced malignant phenotype(Ferrer et al, 2014; Wong 
et al, 2017; Yi et al, 2012). Hyper O-GlcNAcylation has been reported in PDAC and this 
modification has been suggested to aid evading of apoptosis(Bryant et al, 2014). 
Kucharzewska etal (2015)(Kucharzewska et al, 2015) reported decreased UDP-Gal and 
UDP-GlcNAc/UDP-GalNAc in hypoxic cancer cells, indicating increased demand of for 
the synthesis of glycoproteins and glycolipids. In the present study, alterations in the 
concentrations of UDP–GlcNAc and UDP–GalNAc in almost all of KRAS mutants relative 
to their wild type counterparts could indicate changes in protein glycosylation and HBP 
synthesis pathway. 
Compared to KRAS WT, all KRAS mutants except G12S demonstrated increased levels of 
inosine and uridine together with decreased levels of AMP, whilst cell lines with the KRAS 
A146T mutations showed no such changes and KRAS Q61H just exhibited decreased levels 
of AMP. The levels of ATP, GTP and UMP were also reduced in most KRAS mutant 
colorectal cancer cells compared to their corresponding wild type.  However, in direct 
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contrast, KRAS A146T displayed increased levels of GTP and ATP. Nucleotide pool 
imbalance has been proposed to be associated with enhanced mutagenesis and genomic 
instability, which promotes cancer(Kohnken et al, 2015; Papadopoulou et al, 2015). 
Deregulation of nucleotide metabolism is associated with a wide range of pathological 
conditions including cancer(Buj & Aird, 2018; Kohnken et al, 2015). In the present study, the 
significant increase of nucleosides (inosine, uridine) together with decrease of nucleotides 
(AMP, UMP) in the KRAS mutants could reflect rapid nucleotide turnover and salvage 
pathway activity of nucleic acid metabolism. 
Conclusion 
We carried out a comprehensive, unbiased metabonomic analysis of human colorectal cell 
lines (SW48) harbouring a wide range of specific KRAS mutations on common genetic 
backgrounds to broaden and deepen our understanding of the relationships between specific 
genotypes and metabolic phenotypes, or metabotypes, in human colorectal cancer cells. Our 
data further support the notion that KRAS mutations trigger metabolic adaptations to help 
growth and counter stress. Furthermore, this study highlights that colorectal cancer cells 
carrying different KRAS mutations exhibit specific metabolic phenotypes, including 
differences in glycolysis, glutamine utilization, and amino acid, choline and nucleotide 
hexosamine metabolism. These metabolic differences between different KRAS mutants might 
play a role in their different responses to anticancer treatments and hence could be 
investigated to discover novel metabolic vulnerabilities which might be of utility in the 
development of more effective targeted therapies against oncogenic KRAS. Future studies 
could also investigate the relative roles of genetic mutation and nutrient availability in 
directing the metabolic phenotypes of specific cancer cells 
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